Navigation Links
CTI Announces Data Presentations at the 55th American Society of Hematology Annual Meeting
Date:11/7/2013

ubject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities.  Such statements include, but are not limited to, statements regarding CTI's expectations with respect to the development of CTI and its product and product candidate portfolio, the expected commencement of the PERSIST-2 clinical trial in the fourth quarter of 2013 and the expected efficacy and potential benefits of pacritinib (including that pacritinib may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors).  Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks associated with the biopharmaceutical industry in general and with CTI and its product and product candidate portfolio in particular including, among others, risks associated with the following: that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI cannot predict or guarantee the outcome of preclinical and clinical studies, that the second Phase 3 clinical trial of pacritinib will not occur as planned, that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities, that CTI may experience delays in the commencement of preclinical and clinical studies, risks related to the costs of developing pacritinib and CTI's other product candidates, and other risks, including, without limitation, competitive factors, technological developments, that CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI may not achieve previously announced goals and objectives as or when projected, that C
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ambit Biosciences Announces Third Quarter 2013 Operating Results
2. Spherix Announces the Closing of Private Placement of $2,235,000
3. Intelligent Implant Systems Announces 510(k) Clearance of the Marauder Cervical-Thoracic Spinal System
4. karmadata Announces Launch Of App Gallery And The Indicate Investigators App
5. Spherix Announces Additions to Technology Advisory Board in Areas of Licensing and Litigation Support
6. InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock
7. AVS announces its major award winners of 2013
8. Metabolix Announces Third Quarter 2013 Financial Results
9. Discovery Labs Announces Completion of $50 Million Public Offering
10. Life Technologies Announces Third Quarter 2013 Results
11. Colby Pharmaceutical Company Announces Dramatic Results: Novel Technology Increases Influenza Vaccine Protection for Elderly Rhesus Monkeys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... (PRWEB) January 23, 2015 Biofertilizers stimulate ... such as nitrogen and phosphorous through the activities in ... biofertilizers is increasing due to the stress on reducing ... fertilizers. , The report defines and segments the bio ...
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... Johnston, RI (PRWEB) January 22, 2015 ... State , The growing team of brand-neutral, independent consultants, ... CIO Philip Rogers explained that over the years, his ... including , Moroso, Town of Plainfield, as well as ...
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2
... SAN DIEGO, July 23 Anadys Pharmaceuticals, Inc. (Nasdaq: ... financial results on Thursday, July 30, 2009, after the U.S. financial markets ... conference call and webcast on Thursday, July 30, 2009 at 5:00 p.m. ... highlights and to provide an update on its development programs. A ...
... , , , , DALLAS, ... E S S PHARMACEUTICALS, INC. ... European partner, SpePharm , is collecting data from a post approval ... UK showing prevention of oral mucositis. In a multi-center study expected to enroll ...
... Calif., July 23 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) ... 2009 Growth Stock & National Sales Conference on Thursday, July 30, 2009 ... Florida. , , More information about the ... , About Peregrine Pharmaceuticals , ...
Cached Biology Technology:Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results 2MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 2MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 3
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
(Date:1/22/2015)... Jan. 22, 2015 Infinisource has launched its new NXG ... model. The G2 sets a higher standard for collecting attendance ... management solution. With plug-and-play installation, touch screen interface and seamless ... a robust time collection solution for the small to mid-size ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 Following ... the fingerprint reading feature with the iPhone 5S. It ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... with Primary Angle Closure Glaucoma (PACG), a leading cause ... people worldwide, 80% of whom live in Asia. ... Nature Genetics , on 26 August 2012, was ... Institute (SERI)/Singapore National Eye Centre (SNEC), Genome Institute of ...
... 2012 Researchers at the Hebrew University of Jerusalem ... the autonomic nervous system -- reaches the bones and ... The newly discovered pathway has a key role in ... the skeletal resistance to fracture throughout one,s entire life, ...
... Operon, one of the pioneers and key providers of ... 2500 and an Illumina MiSeq sequencer to its fleet ... will be able to provide customers with NGS services ... Whilst technological innovation has improved the general performance of ...
Cached Biology News:Singapore scientists find genes associated with glaucoma, a major cause of eye blindness 2Singapore scientists find genes associated with glaucoma, a major cause of eye blindness 3New neural pathway controlling skeletal development discovered 2New neural pathway controlling skeletal development discovered 3
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
...
... the first fully genetically encoded fluorescent sensor ... hydrogen peroxide (H2O2), one of the main ... basis of yellow fluorescent protein inserted into ... OxyR (OxyR-RD), HyPer demonstrates submicromolar affinity to ...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: